234 related articles for article (PubMed ID: 22155545)
1. Relationships between the islets blood flow, nitric oxide, insulin, and cytosolic calcium in rat pancreatic islets: effects of DPP-IV inhibitor vildagliptin.
Akarte AS; Srinivasan BP; Gandhi S
Eur J Pharm Sci; 2012 Apr; 45(5):546-51. PubMed ID: 22155545
[TBL] [Abstract][Full Text] [Related]
2. Vildagliptin selectively ameliorates GLP-1, GLUT4, SREBP-1c mRNA levels and stimulates β-cell proliferation resulting in improved glucose homeostasis in rats with streptozotocin-induced diabetes.
Akarte AS; Srinivasan BP; Gandhi S
J Diabetes Complications; 2012; 26(4):266-74. PubMed ID: 22626875
[TBL] [Abstract][Full Text] [Related]
3. A novel long acting DPP-IV inhibitor PKF-275-055 stimulates β-cell proliferation resulting in improved glucose homeostasis in diabetic rats.
Akarte AS; Srinivasan BP; Gandhi S
Biochem Pharmacol; 2012 Jan; 83(2):241-52. PubMed ID: 22015634
[TBL] [Abstract][Full Text] [Related]
4. The DPP-4 inhibitor vildagliptin increases pancreatic beta cell mass in neonatal rats.
Duttaroy A; Voelker F; Merriam K; Zhang X; Ren X; Subramanian K; Hughes TE; Burkey BF
Eur J Pharmacol; 2011 Jan; 650(2-3):703-7. PubMed ID: 21070766
[TBL] [Abstract][Full Text] [Related]
5. Vildagliptin ameliorates oxidative stress and pancreatic beta cell destruction in type 1 diabetic rats.
Ávila Dde L; Araújo GR; Silva M; Miranda PH; Diniz MF; Pedrosa ML; Silva ME; de Lima WG; Costa DC
Arch Med Res; 2013 Apr; 44(3):194-202. PubMed ID: 23523961
[TBL] [Abstract][Full Text] [Related]
6. Chronic DPP-IV inhibition with PKF-275-055 attenuates inflammation and improves gene expressions responsible for insulin secretion in streptozotocin induced diabetic rats.
Akarte AS; Srinivasan BP; Gandhi S; Sole S
Eur J Pharm Sci; 2012 Sep; 47(2):456-63. PubMed ID: 22800967
[TBL] [Abstract][Full Text] [Related]
7. Improved meal-related insulin processing contributes to the enhancement of B-cell function by the DPP-4 inhibitor vildagliptin in patients with type 2 diabetes.
Ahrén B; Pacini G; Tura A; Foley JE; Schweizer A
Horm Metab Res; 2007 Nov; 39(11):826-9. PubMed ID: 17992639
[TBL] [Abstract][Full Text] [Related]
8. Impact of the dipeptidyl peptidase-4 inhibitor vildagliptin on glucose tolerance and β-cell function and mass in insulin receptor substrate-2-knockout mice fed a high-fat diet.
Sato K; Nakamura A; Shirakawa J; Muraoka T; Togashi Y; Shinoda K; Orime K; Kubota N; Kadowaki T; Terauchi Y
Endocrinology; 2012 Mar; 153(3):1093-102. PubMed ID: 22315446
[TBL] [Abstract][Full Text] [Related]
9. Effects of long-term treatment with the dipeptidyl peptidase-4 inhibitor vildagliptin on islet endocrine cells in non-obese type 2 diabetic Goto-Kakizaki rats.
Inaba W; Mizukami H; Kamata K; Takahashi K; Tsuboi K; Yagihashi S
Eur J Pharmacol; 2012 Sep; 691(1-3):297-306. PubMed ID: 22820107
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of dipeptidyl peptidase-4 by vildagliptin during glucagon-like Peptide 1 infusion increases liver glucose uptake in the conscious dog.
Edgerton DS; Johnson KM; Neal DW; Scott M; Hobbs CH; Zhang X; Duttaroy A; Cherrington AD
Diabetes; 2009 Jan; 58(1):243-9. PubMed ID: 18840785
[TBL] [Abstract][Full Text] [Related]
11. Liraglutide, but not vildagliptin, restores normoglycaemia and insulin content in the animal model of type 2 diabetes, Psammomys obesus.
Vedtofte L; Bodvarsdottir TB; Gotfredsen CF; Karlsen AE; Knudsen LB; Heller RS
Regul Pept; 2010 Feb; 160(1-3):106-14. PubMed ID: 20005262
[TBL] [Abstract][Full Text] [Related]
12. DPP-4 inhibition improves glucose tolerance and increases insulin and GLP-1 responses to gastric glucose in association with normalized islet topography in mice with beta-cell-specific overexpression of human islet amyloid polypeptide.
Ahrén B; Winzell MS; Wierup N; Sundler F; Burkey B; Hughes TE
Regul Pept; 2007 Oct; 143(1-3):97-103. PubMed ID: 17482289
[TBL] [Abstract][Full Text] [Related]
13. DPP4 inhibitor vildagliptin preserves β-cell mass through amelioration of endoplasmic reticulum stress in C/EBPB transgenic mice.
Shimizu S; Hosooka T; Matsuda T; Asahara S; Koyanagi-Kimura M; Kanno A; Bartolome A; Etoh H; Fuchita M; Teruyama K; Takahashi H; Inoue H; Mieda Y; Hashimoto N; Seino S; Kido Y
J Mol Endocrinol; 2012 Oct; 49(2):125-35. PubMed ID: 22822047
[TBL] [Abstract][Full Text] [Related]
14. Effects of combination therapy with vildagliptin and valsartan in a mouse model of type 2 diabetes.
Miyagawa K; Kondo T; Goto R; Matsuyama R; Ono K; Kitano S; Kawasaki S; Igata M; Kawashima J; Matsumura T; Motoshima H; Araki E
Cardiovasc Diabetol; 2013 Nov; 12():160. PubMed ID: 24188631
[TBL] [Abstract][Full Text] [Related]
15. The effects of dipeptidyl-peptidase-IV inhibitor, vildagliptin, on the exocrine pancreas in spontaneously diabetic Goto-Kakizaki rats.
Mizukami H; Inaba W; Takahashi K; Kamata K; Tsuboi K; Yagihashi S
Pancreas; 2013 Jul; 42(5):786-94. PubMed ID: 23774700
[TBL] [Abstract][Full Text] [Related]
16. Vildagliptin in clinical practice: a review of literature.
Banerjee M; Younis N; Soran H
Expert Opin Pharmacother; 2009 Nov; 10(16):2745-57. PubMed ID: 19874253
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of DPP-4 with vildagliptin improved insulin secretion in response to oral as well as "isoglycemic" intravenous glucose without numerically changing the incretin effect in patients with type 2 diabetes.
Vardarli I; Nauck MA; Köthe LD; Deacon CF; Holst JJ; Schweizer A; Foley JE
J Clin Endocrinol Metab; 2011 Apr; 96(4):945-54. PubMed ID: 21239518
[TBL] [Abstract][Full Text] [Related]
18. Acute and chronic effects of the incretin enhancer vildagliptin in insulin-resistant rats.
Burkey BF; Li X; Bolognese L; Balkan B; Mone M; Russell M; Hughes TE; Wang PR
J Pharmacol Exp Ther; 2005 Nov; 315(2):688-95. PubMed ID: 16027230
[TBL] [Abstract][Full Text] [Related]
19. Mechanisms of action of the dipeptidyl peptidase-4 inhibitor vildagliptin in humans.
Ahrén B; Schweizer A; Dejager S; Villhauer EB; Dunning BE; Foley JE
Diabetes Obes Metab; 2011 Sep; 13(9):775-83. PubMed ID: 21507182
[TBL] [Abstract][Full Text] [Related]
20. The dipeptidyl peptidase-4 inhibitor vildagliptin has the capacity to repair β-cell dysfunction and insulin resistance.
Horie A; Tokuyama Y; Ishizuka T; Suzuki Y; Marumo K; Oshikiri K; Ide K; Sunaga M; Kanatsuka A
Horm Metab Res; 2014 Oct; 46(11):814-8. PubMed ID: 24977657
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
